HOOKIPA Pharma Inc., a biotechnology company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on December 22, 2023. The company is seeking to have the Registration Statement become effective on January 4, 2024, at 4:01 pm Eastern Time. This request was made under Rule 461 of the Securities Act of 1933. HOOKIPA Pharma's Chief Financial Officer, Reinhard Kandera, signed the request, indicating the company's awareness of its obligations under the Act. The company's outside counsel, Goodwin Procter LLP, will be available to address any questions from the SEC, with Finnbarr D. Murphy being the primary contact.

HOOKIPA Pharma Inc., a biotechnology company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on December 22, 2023. The company is seeking to have the Registration Statement become effective on January 4, 2024, at 4:01 pm Eastern Time. This request was made under Rule 461 of the Securities Act of 1933. HOOKIPA Pharma's Chief Financial Officer, Reinhard Kandera, signed the request, indicating the company's awareness of its obligations under the Act. The company's outside counsel, Goodwin Procter LLP, will be available to address any questions from the SEC, with Finnbarr D. Murphy being the primary contact.